Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

Shenduo Li; Guilherme Sacchi de Camargo Correia; Jing Wang; Rami Manochakian; Yujie Zhao; Yanyan Lou

doi:10.3390/cancers15112899

Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

Shenduo Li, Guilherme Sacchi de Camargo Correia, Jing Wang, Rami Manochakian, Yujie Zhao, Yanyan Lou

Hematology / Oncology / Cancer Center / Breast Clinic

Research output: Contribution to journal › Review article › peer-review

Abstract

Lung cancer remains the leading cause of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC) is the most common type and is still incurable for most patients at the advanced stage. Targeted therapy is an effective treatment that has significantly improved survival in NSCLC patients with actionable mutations. However, therapy resistance occurs widely among patients leading to disease progression. In addition, many oncogenic driver mutations in NSCLC still lack targeted agents. New drugs are being developed and tested in clinical trials to overcome these challenges. This review aims to summarize emerging targeted therapy that have been conducted or initiated through first-in-human clinical trials in the past year.

Original language	English (US)
Article number	2899
Journal	Cancers
Volume	15
Issue number	11
DOIs	https://doi.org/10.3390/cancers15112899
State	Published - Jun 2023

Keywords

EGFR
NSCLC
clinical trial
first-in-human
phase I/II
targeted therapy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3390/cancers15112899

Cite this

@article{6cbf74d0e18c4df588308f0b01d6c5f6,

title = "Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer",

abstract = "Lung cancer remains the leading cause of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC) is the most common type and is still incurable for most patients at the advanced stage. Targeted therapy is an effective treatment that has significantly improved survival in NSCLC patients with actionable mutations. However, therapy resistance occurs widely among patients leading to disease progression. In addition, many oncogenic driver mutations in NSCLC still lack targeted agents. New drugs are being developed and tested in clinical trials to overcome these challenges. This review aims to summarize emerging targeted therapy that have been conducted or initiated through first-in-human clinical trials in the past year.",

keywords = "EGFR, NSCLC, clinical trial, first-in-human, phase I/II, targeted therapy",

author = "Shenduo Li and {de Camargo Correia}, {Guilherme Sacchi} and Jing Wang and Rami Manochakian and Yujie Zhao and Yanyan Lou",

note = "Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = jun,

doi = "10.3390/cancers15112899",

language = "English (US)",

volume = "15",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "11",

}

TY - JOUR

T1 - Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

AU - Li, Shenduo

AU - de Camargo Correia, Guilherme Sacchi

AU - Wang, Jing

AU - Manochakian, Rami

AU - Zhao, Yujie

AU - Lou, Yanyan

PY - 2023/6

Y1 - 2023/6

N2 - Lung cancer remains the leading cause of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC) is the most common type and is still incurable for most patients at the advanced stage. Targeted therapy is an effective treatment that has significantly improved survival in NSCLC patients with actionable mutations. However, therapy resistance occurs widely among patients leading to disease progression. In addition, many oncogenic driver mutations in NSCLC still lack targeted agents. New drugs are being developed and tested in clinical trials to overcome these challenges. This review aims to summarize emerging targeted therapy that have been conducted or initiated through first-in-human clinical trials in the past year.

AB - Lung cancer remains the leading cause of cancer-related mortality worldwide. Non-small-cell lung cancer (NSCLC) is the most common type and is still incurable for most patients at the advanced stage. Targeted therapy is an effective treatment that has significantly improved survival in NSCLC patients with actionable mutations. However, therapy resistance occurs widely among patients leading to disease progression. In addition, many oncogenic driver mutations in NSCLC still lack targeted agents. New drugs are being developed and tested in clinical trials to overcome these challenges. This review aims to summarize emerging targeted therapy that have been conducted or initiated through first-in-human clinical trials in the past year.

KW - EGFR

KW - NSCLC

KW - clinical trial

KW - first-in-human

KW - phase I/II

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85161302603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85161302603&partnerID=8YFLogxK

U2 - 10.3390/cancers15112899

DO - 10.3390/cancers15112899

M3 - Review article

AN - SCOPUS:85161302603

SN - 2072-6694

VL - 15

JO - Cancers

JF - Cancers

IS - 11

M1 - 2899

ER -

Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this